Martin Hoenigl1, Antoine Chaillon, David J Moore, Sheldon R Morris, Davey M Smith, Susan J Little. 1. *Division of Infectious Diseases, Department of Medicine, University of California San Diego (UCSD), La Jolla, San Diego, CA; †Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria; ‡Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; §Department of Psychiatry, University of California San Diego (UCSD), La Jolla, San Diego, CA; and ‖Veterans Affairs Healthcare System, San Diego, CA.
Abstract
BACKGROUND: It remains unclear if methamphetamine is merely associated with high-risk behavior or if methamphetamine use causes high-risk behavior. Determining this would require a randomized controlled trial, which is clearly not ethical. A possible surrogate would be to investigate individuals before and after starting the use of methamphetamine. METHODS: We performed a cohort study to analyze recent self-reported methamphetamine use and sexual risk behavior among 8905 men who have sex with men (MSM) receiving the "Early Test," a community-based HIV screening program in San Diego, CA, between April 2008 and July 2014 (total 17,272 testing encounters). Sexual risk behavior was evaluated using a previously published risk behavior score [San Diego Early Test (SDET) score] that predicts risk of HIV acquisition. RESULTS: Methamphetamine use during the last 12 months (hereafter, recent-meth) was reported by 754/8905 unique MSM (8.5%). SDET scores were significantly higher in the 754 MSM with recent-meth use compared with the 5922 MSM who reported that they have never used methamphetamine (P < 0.001). Eighty-two repeat testers initiated methamphetamine between testing encounter, with significantly higher SDET scores after starting methamphetamine [median 5 (interquartile range, 2-7) at recent-meth versus median 3 (interquartile range, 0-5) at never-meth; P < 0.001, respectively]. CONCLUSIONS: Given the ethical impossibility of conducting a randomized controlled trial, the results presented here provide the strongest evidence yet that initiation of methamphetamine use increases sexual risk behavior among HIV-uninfected MSM. Until more effective prevention or treatment interventions are available for methamphetamine users, HIV-uninfected MSM who use methamphetamine may represent ideal candidates for alternative effective prevention interventions (ie, preexposure prophylaxis).
BACKGROUND: It remains unclear if methamphetamine is merely associated with high-risk behavior or if methamphetamine use causes high-risk behavior. Determining this would require a randomized controlled trial, which is clearly not ethical. A possible surrogate would be to investigate individuals before and after starting the use of methamphetamine. METHODS: We performed a cohort study to analyze recent self-reported methamphetamine use and sexual risk behavior among 8905 men who have sex with men (MSM) receiving the "Early Test," a community-based HIV screening program in San Diego, CA, between April 2008 and July 2014 (total 17,272 testing encounters). Sexual risk behavior was evaluated using a previously published risk behavior score [San Diego Early Test (SDET) score] that predicts risk of HIV acquisition. RESULTS:Methamphetamine use during the last 12 months (hereafter, recent-meth) was reported by 754/8905 unique MSM (8.5%). SDET scores were significantly higher in the 754 MSM with recent-meth use compared with the 5922 MSM who reported that they have never used methamphetamine (P < 0.001). Eighty-two repeat testers initiated methamphetamine between testing encounter, with significantly higher SDET scores after starting methamphetamine [median 5 (interquartile range, 2-7) at recent-meth versus median 3 (interquartile range, 0-5) at never-meth; P < 0.001, respectively]. CONCLUSIONS: Given the ethical impossibility of conducting a randomized controlled trial, the results presented here provide the strongest evidence yet that initiation of methamphetamine use increases sexual risk behavior among HIV-uninfected MSM. Until more effective prevention or treatment interventions are available for methamphetamine users, HIV-uninfected MSM who use methamphetamine may represent ideal candidates for alternative effective prevention interventions (ie, preexposure prophylaxis).
Authors: Peter Freeman; Bendu C Walker; D Robert Harris; Robert Garofalo; Nancy Willard; Jonathan M Ellen Journal: Arch Pediatr Adolesc Med Date: 2011-08
Authors: Sheldon R Morris; Susan J Little; Terry Cunningham; Richard S Garfein; Douglas D Richman; Davey M Smith Journal: Ann Intern Med Date: 2010-06-15 Impact factor: 25.391
Authors: Lydia N Drumright; Susan J Little; Steffanie A Strathdee; Donald J Slymen; Maria Rosario G Araneta; Vanessa L Malcarne; Eric S Daar; Pamina M Gorbach Journal: J Acquir Immune Defic Syndr Date: 2006-11-01 Impact factor: 3.731
Authors: Pamina M Gorbach; Lydia N Drumright; Marjan Javanbakht; Sergei L Pond; Christopher H Woelk; Eric S Daar; Susan J Little Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Hanne Thiede; Richard A Jenkins; James W Carey; Rebecca Hutcheson; Katherine K Thomas; Ronald D Stall; Edward White; Iris Allen; Roberto Mejia; Matthew R Golden Journal: Am J Public Health Date: 2008-04-29 Impact factor: 9.308
Authors: Jeb Jones; Martin Hoenigl; Aaron J Siegler; Patrick S Sullivan; Susan Little; Eli Rosenberg Journal: Sex Transm Dis Date: 2017-05 Impact factor: 2.830
Authors: Matthew J Mimiaga; David W Pantalone; Katie B Biello; Jackie M White Hughto; John Frank; Conall O'Cleirigh; Sari L Reisner; Arjee Restar; Kenneth H Mayer; Steven A Safren Journal: AIDS Care Date: 2019-03-19
Authors: Sean P Colyer; Nathan J Lachowsky; Zishan Cui; Julia Zhu; Heather L Armstrong; Matthew Taylor; Joshua Edward; Gbolahan Olarewaju; Robert S Hogg; Eric A Roth; David M Moore Journal: Drug Alcohol Depend Date: 2018-02-08 Impact factor: 4.492
Authors: Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2016-08-02 Impact factor: 4.147
Authors: Martin Hoenigl; Antoine Chaillon; Sanjay R Mehta; Davey M Smith; Joshua Graff-Zivin; Susan J Little Journal: J Infect Date: 2016-08-11 Impact factor: 6.072
Authors: Suzan M Walters; Bethany Coston; Alan Neaigus; Alexis V Rivera; Lila Starbuck; Valentina Ramirez; Kathleen H Reilly; Sarah L Braunstein Journal: Int J Drug Policy Date: 2020-02-21
Authors: Cheríe S Blair; Marjan Javanbakht; W Scott Comulada; E India Richter; Robert Bolan; Steven Shoptaw; Pamina M Gorbach Journal: Int J STD AIDS Date: 2020-08-04 Impact factor: 1.359